Watanabe Shinya
Department of Neurosurgery, Mito Kyodo General Hospital, Tsukuba University Hospital Mito Area Medical Education Center.
No Shinkei Geka. 2024 Jul;52(4):851-858. doi: 10.11477/mf.1436204984.
In contrast to other cancer research areas, the development of chemotherapy and radiotherapy for meningiomas has been challenging, lacking standardized criteria for assessing treatment response and progression. Although efforts by RANO have proposed evaluation criteria, a consensus on effective evaluation parameters for meningiomas remains elusive. This paper underscores the importance of establishing efficacy endpoints in clinical trials, compares efficacy assessment in meningioma research with other solid tumor areas, and outlines the challenges ahead in meningioma research. Recent analyses revealed the absence of consensus on efficacy endpoints in meningioma trials, complicating trial design and hindering cross-trial comparisons. The unique anatomical constraints and histological variability of meningiomas pose challenges in determining appropriate efficacy measures. To address these challenges, future research must focus on accumulating prognostic data, standardizing evaluation criteria, and considering multiple endpoints in trial designs. Akin to other cancer areas, investigating targeted therapies and establishing international consensus on efficacy endpoints are crucial steps forward.
与其他癌症研究领域相比，脑膜瘤化疗和放疗的发展一直具有挑战性，缺乏评估治疗反应和进展的标准化标准。尽管RANO做出了努力并提出了评估标准，但对于脑膜瘤有效评估参数仍未达成共识。本文强调了在临床试验中建立疗效终点的重要性，将脑膜瘤研究中的疗效评估与其他实体瘤领域进行了比较，并概述了脑膜瘤研究面临的挑战。最近的分析表明，脑膜瘤试验中在疗效终点方面缺乏共识，这使得试验设计复杂化并阻碍了跨试验比较。脑膜瘤独特的解剖学限制和组织学变异性在确定合适的疗效测量方法方面带来了挑战。为应对这些挑战，未来的研究必须专注于积累预后数据、标准化评估标准，并在试验设计中考虑多个终点。与其他癌症领域一样，研究靶向治疗并就疗效终点达成国际共识是向前迈出的关键步骤。
